Home›Stock Screener›Mangalam Drugs & Organics›Quarterly Results

Mangalam Drugs & Organics Quarterly Results

Latest Quarter Net Profit
₹-13 Cr
QMar 2026
Quarterly Results

Mangalam Drugs & Organics quarterly results. In Mar 2026, Mangalam Drugs & Organics (MANGALAM) reported revenue ₹67 Cr and net profit ₹-13 Cr — revenue -8.2% YoY. For annual financials, live price and key ratios, visit Mangalam Drugs & Organics share price screener.

MANGALAM Quarterly Results — Revenue, Profit & EPS Highlights

Mangalam Drugs & Organics latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Review MANGALAM price earnings ratio to evaluate earnings-based valuation against sector peers.

  • Revenue of ₹67 Cr in Mar 2026 (+17.5% vs Jun 2026, -8.2% vs Mar 2025)
  • Net Profit of ₹-13 Cr in Mar 2026 (-62.5% vs Jun 2026)
  • EBITDA of ₹-6 Cr in Mar 2026 (-700.0% vs Jun 2026)
  • Operating Margin of -8.0% in Mar 2026 (-10.0pp vs Jun 2026)
  • Earnings Per Share of ₹-8.48 in Mar 2026 (-75.6% vs Jun 2026)

Mangalam Drugs & Organics Quarterly Results — Revenue, EBITDA, Net Profit & EPS

MANGALAM quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.

Metric Mar 2026 Jun 2026 Sept 2025 Mar 2025 Jun 2025 QoQ YoY
Revenue (₹ Cr) 67 57 49 73 57 17.5% -8.2%
Net Profit (₹ Cr) -13 -8 -7 0 -14 - -
EBITDA (₹ Cr) -6 1 -3 10 -5 - -
EPS (₹) -8.48 -4.83 -4.64 0.04 -8.72 - -
Operating Margin (%) -8.0% 2.0% -6.0% 14.0% -8.0% - -

MANGALAM Share Price Trend — 1-Year Movement Across Quarterly Results

Mangalam Drugs & Organics 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Check MANGALAM market capitalization to track the company's total market size over time.

Profitability Ratios

Profit Margin -19.4%
EBITDA Margin -9.0%
Operating Margin -8.0%
ROE (Annual) -50.5%

Balance Sheet Highlights

Total Assets ₹315 Cr
Total Equity ₹103 Cr
Current Assets ₹156 Cr
Current Liabilities ₹15 Cr

Cash Flow Analysis

Operating Cash Flow ₹43 Cr
Investing Cash Flow ₹-20 Cr
Financing Cash Flow ₹-22 Cr
Net Cash Flow ₹1 Cr

Current Market Data

Current Price ₹31.86
Exchange NSE
Last Updated Oct 06, 2026

Revenue Trend (₹ Cr)

Mar 2025 73
Sept 2025 49
Jun 2026 57
Mar 2026 67

Net Profit Trend (₹ Cr)

Mar 2025 0
Sept 2025 -7
Jun 2026 -8
Mar 2026 -13

Operating Margin Trend (%)

Mar 2025 14.0%
Sept 2025 -6.0%
Jun 2026 2.0%
Mar 2026 -8.0%

MANGALAM vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap

Mangalam Drugs & Organics latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.

Company Latest Quarter Market Cap (₹ Cr) Price (₹) Revenue (₹ Cr) Net Profit (₹ Cr) Rev QoQ % Rev YoY % Profit Margin % P/E Ratio
Sun Pharmaceutical
Mar 2026 		₹432,120.23 Cr 1804.1 15,018 2,710 -5.6% - 18.0% 159.7
Divis Laboratories
Mar 2026 		₹244,124.91 Cr 9550.0 2,986 751 -5.0% - 25.2% 337.3
Torrent Pharmaceuti…
Mar 2026 		₹188,719.51 Cr 4772.0 4,111 364 +27.7% +42.2% 8.9% 414.6
Zydus Life Science
Mar 2026 		₹113,615.69 Cr 1159.5 7,569 1,341 -4.3% - 17.7% 91.7
Laurus Labs
Mar 2026 		₹109,629.35 Cr 2050.0 1,823 282 -10.5% - 15.5% 396.5
Sector Quarterly Performance Comparison
Healthcare sector • Latest quarterly results
▲ Positive Growth
▼ Negative Growth
- No Data

QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores